Evidence map›Paper›PMID 41760995›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

The evolving landscape of amyloid-targeting therapies in Alzheimer's disease: progress and challenges.

Binbin Zhang, Xiaoyun Yu, Xin Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Binbin ZhangDepartment of Neurology, The Third People's Hospital of Dalian, Dalian, Liaoning Province, China.
Xiaoyun YuDepartment of Neurology, The Third People's Hospital of Dalian, Dalian, Liaoning Province, China.
Xin ZhangDepartment of Neurology, The Third People's Hospital of Dalian, Dalian, Liaoning Province, China. junanzhangxin@126.com.ORCID http://orcid.org/0000-0003-1730-8952

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is the leading cause of dementia worldwide. Amyloid-β (Aβ) accumulation has long guided therapeutic development, though early β- and γ-secretase inhibitors failed to demonstrate clinical benefit.

methodsA narrative review was conducted based on a structured search of MEDLINE, Embase, and ClinicalTrials.gov, supplemented by manual screening of key reviews and Phase 3 trial reports on amyloid-targeting therapies.

resultsMonoclonal antibodies including aducanumab, lecanemab, and donanemab achieve significant amyloid clearance and modest slowing of cognitive decline in Phase 3 trials, validating amyloid reduction as a disease-modifying pathway. However, clinical benefits are limited, amyloid-related imaging abnormalities (ARIA) remain safety concerns, and high costs restrict accessibility. Persistent therapeutic gaps reflect the multifactorial pathology of AD, including tau, neuroinflammation, and vascular dysfunction.

conclusionsAmyloid-targeting therapies represent the first validated disease-modifying strategy for AD but are not definitive solutions. Future directions include earlier intervention, combination approaches, improved antibody design, and scalable biomarker implementation to enhance real-world impact.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalAnimalsHumansAmyloid beta-PeptidesAntibodies, MonoclonalAlzheimer’s diseaseAmyloid-targeting therapiesDisease modification

Identifiers

PMID41760995

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.